This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Anti-c-MET is the receptor for hepatocyte growth factor (also known as scatter factor, HGF/SF), and belongs to the tyrosine kinase superfamily. Interaction of c-Met with HGF results in autophosphorylation of c-Met at multiple tyrosines. Phosphorylation of Y1234/1235 in the c-Met kinase domain is critical to kinase activation. When phosphorylated, Y1349 and Y1356, along with surrounding amino acids, form a unique bidentate docking site for substrates such as Gab1, Grb2, phosphatidylinositol 3-kinase (PI3K) and others. C-Met mainly uses the Gab1 scaffolding adaptor in its initial step of signal transmission. Well-characterized downstream signalling pathways that are activated by c-Met include the ERK/MAPK, PI3K–Akt/PKB, Crk–Rap and Rac–Pak pathways, resulting in proliferation and increased cell survival. Anti-Phospho cMET was developed with NCI and is ideal for Cancer Research.
This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to residues surrounding Y1349 and Y1356 of human c-Met protein.